Northern Trust
QNCX icon

Northern Trust’s Quince Therapeutics QNCX Stock Holding History

Northern Trust’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-330
Closed -$6.68K – 4539
2026
Q1 		$6.68K Sell
330
-201
-38% -$40.3K ﹤0.01% 4385
2025
Q4 		$356K Buy
531
+207
+64% +$104K ﹤0.01% 3777
2025
Q3 		$105K Sell
324
-63
-16% -$21K ﹤0.01% 4122
2025
Q2 		$128K Hold
387
– – ﹤0.01% 4059
2025
Q1 		$103K Buy
387
+134
+53% +$40.9K ﹤0.01% 4108
2024
Q4 		$94.5K Buy
253
+83
+49% +$24.9K ﹤0.01% 4162
2024
Q3 		$26.4K Hold
170
– – ﹤0.01% 4307
2024
Q2 		$25.5K Hold
170
– – ﹤0.01% 4306
2024
Q1 		$36.1K Sell
170
-49
-22% -$12.2K ﹤0.01% 4271
2023
Q4 		$46.1K Hold
219
– – ﹤0.01% 4247
2023
Q3 		$49.1K Hold
219
– – ﹤0.01% 4175
2023
Q2 		$66K Buy
219
+17
+8% +$5.29K ﹤0.01% 4146
2023
Q1 		$63.1K Buy
202
+33
+20% +$6.46K ﹤0.01% 4205
2022
Q4 		$21.5K Sell
169
-60
-26% -$10K ﹤0.01% 4473
2022
Q3 		$61K Hold
229
– – ﹤0.01% 4272
2022
Q2 		$102K Sell
229
-753
-77% -$532K ﹤0.01% 4161
2022
Q1 		$1.22M Buy
982
+14
+1% +$19.1K ﹤0.01% 3340
2021
Q4 		$2.44M Sell
968
-36
-4% -$220K ﹤0.01% 3127
2021
Q3 		$18.4M Sell
1,004
-22
-2% -$350K ﹤0.01% 1858
2021
Q2 		$10.9M Buy
1,026
+178
+21% +$1.49M ﹤0.01% 2306
2021
Q1 		$6.11M Sell
848
-49
-5% -$353K ﹤0.01% 2626
2020
Q4 		$4.98M Sell
897
-7
-0.8% -$62K ﹤0.01% 2687
2020
Q3 		$9.04M Buy
904
+29
+3% +$264K ﹤0.01% 2167
2020
Q2 		$8.1M Buy
875
+240
+38% +$2.2M ﹤0.01% 2229
2020
Q1 		$5.8M Buy
635
+17
+3% +$168K ﹤0.01% 2207
2019
Q4 		$6.93M Buy
618
+386
+166% +$2.33M ﹤0.01% 2397
2019
Q3 		$1.16M Buy
232
+115
+98% +$708K ﹤0.01% 3344
2019
Q2 		$991K Buy
+117
New +$699K ﹤0.01% 3361

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Northern Trust's QNCX Position: Q2 2026 in Review

Northern Trust sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 330 shares — an estimated $6.68K sold.

Northern Trust first reported a position in QNCX in Q2 2019 and held it in 28 quarters. The position peaked at $18.4M in Q3 2021. 26 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • Northern Trust reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Northern Trust sold 330 Quince Therapeutics shares in Q2 2026, an estimated $6.68K.
  • Northern Trust first reported a position in Quince Therapeutics in Q2 2019 and held it in 28 quarters.
  • Northern Trust's Quince Therapeutics position peaked at $18.4M in Q3 2021.
  • 26 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.